Dotmatics at the Drug Discovery Innovation Forum 2025
Dotmatics will participate in the exclusive 16th Annual Drug Discovery to Development Innovation Leadership Forum on September 10-11, 2025, at the Hyatt Regency Barcelona Tower, Spain, an invite-only event for up to 200 top executives and scientists focused on cutting-edge pharmaceutical innovation areas such as generative AI, explainable AI, biomarker-based discovery, and precision medicine.
Attend the 16th Annual Drug Discovery Innovation Forum 2025 with Dotmatics
The 16th Annual Drug Discovery to Development Innovation Leadership Forum 2025 is an exclusive, invite-only gathering of up to 200 C-suite executives, visionary scientists, and strategic decision-makers shaping the next era of pharmaceutical innovation.
This is more than a conference—it's a mission-critical forum for those leading the most high-risk, high-reward phase of therapeutic development.
With billions in projected investment flowing into generative AI, explainable AI (XAI), biomarker-based discovery, and precision medicine, this summit focuses on the areas most poised for disruption and action.
Meet us at Booth No. 2.
Event Details
- Dates: 10-11 September 2025
- Location: Hyatt Regency Barcelona Tower, Spain
Related
Bio-IT World
Dotmatics will sponsor and exhibit at the 25th annual Bio-IT World Conference & Expo, held May 19-21, 2026, at the Omni Boston Hotel at the Seaport, where over 2,900 leaders from biopharma, clinical research, healthcare, informatics, and technology gather to showcase innovative technologies and analytic approaches advancing precision medicine.
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.
Dotmatics on KSNV: The Role of AI in Accelerating the Discovery of Life-Saving Medicines
In a KSNV interview, Phil Mounteney, VP of Science and Technology at Dotmatics, discusses how their AI-ready platform is revolutionizing drug discovery by enabling scientists to develop life-saving medicines more quickly and cost-effectively, potentially reducing drug development timelines from ten years to just a few and advancing personalized medicine.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.
CIO.Inc: Can AI Finally Close the Gap Between Science and Software?
Alister Campbell, VP at Dotmatics, explains in CIO.Inc how AI is addressing the longstanding "last mile" challenge of translating scientific models into scalable software applications, enabling faster, more cost-effective development of personalized medicines and potentially revolutionizing patient access to safer therapeutics.